EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Promotion of vessel regression by local VEGF-A blockade improves the survival rate of corneal transplants

Zhe Chen, Wei Zhang, Mert Mestanoglu, Claus Cursiefen, Felix Bock

Experimental Eye Research · 2025

DOI: 10.1016/j.exer.2025.110652 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Eye Research, 2025. Verfasst von Zhe Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Graft Survival, Corneal Transplantation, Vascular Endothelial Growth Factor A, Receptors, Vascular Endothelial Growth Factor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Universität zu Köln, University of Cologne Center for Molecular Medicine Cologne.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To primarily evaluate the efficacy of different topical vascular endothelial growth factor (VEGF) blocking treatments, namely Aflibercept and Bevacizumab, in promoting regression of pathologic corneal neovascularization (NV) and secondarily to investigate their effects on graft survival in a high-risk mouse corneal transplantation model. In addition, the immune modulatory effects were assessed. After 14 days of suture-induced, inflammatory corneal NV, sutures were removed. Anti-VEGF eye drops or vehicle controls were applied topically 3 times daily for one week. After 21 days, the regression of blood vessels (BVs) and lymphatic vessels (LVs) was assessed via immunofluorescence staining. In addition, corneal grafting was performed in another set of mice. Therefore, allogeneic donor corneas from C57BL/6N mice were used and graft survival was monitored weekly for 8 weeks. Finally, hem-and lymphangiogenesis as well as the phenotype of antigen-presenting cells (APCs) in draining lymph nodes (dLNs) and corneas were analyzed by immunohistochemistry and FACS, respectively. Both, Aflibercept and Bevacizumab eye drops supported the regression of both blood and lymphatic vessels. Aflibercept-treated corneas demonstrated decreased APC activation in the dLNs after treatment at day 21. In the high-risk transplantation model, both therapeutics could improve graft survival rates (Aflibercept: 60 %, P = 0.0091; Bevacizumab: 50 %, P = 0.0547) compared to control (10 %). Eight weeks post-transplantation, both treatment arms displayed decreased APC recruitment and an increased expression of Foxp3 on CD4+CD25+ T cells. Our study demonstrates that different topically applied anti-VEGF eye drops effectively reduce pre-existing corneal neovascularization and thereby improve subsequent high-risk corneal transplantation. This translational approach could become a promising strategy to improve the clinical outcome of high risk keratoplasty in patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft SurvivalCorneal TransplantationVascular Endothelial Growth Factor AReceptors, Vascular Endothelial Growth FactorCorneal NeovascularizationAngiogenesis InhibitorsBevacizumabRecombinant Fusion ProteinsCorneaAnimalsMice, Inbred C57BLMiceDisease Models, AnimalLymphangiogenesisLymphatic VesselsFlow CytometryOphthalmic Solutions

Stichwörter der Autor:innen

AfliberceptBevacizumabCorneal transplantationImmune modulationNeovascularization regression

Substanzen

afliberceptVascular Endothelial Growth Factor AReceptors, Vascular Endothelial Growth FactorAngiogenesis InhibitorsBevacizumabRecombinant Fusion Proteinsvascular endothelial growth factor A, mouseOphthalmic Solutions

Autor:innen und Institutionen

  • Department of Ophthalmology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Department of Ophthalmology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany; CECAD Clu…
  • Department of Ophthalmology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany. Electroni…

Förderung

  • Deutsche Forschungsgemeinschaft
  • Universität zu Köln
  • University of Cologne Center for Molecular Medicine Cologne
  • China Scholarship Council

Zitieren

APA

Chen, Z., Zhang, W., Mestanoglu, M., Cursiefen, C., & Bock, F. (2025). Promotion of vessel regression by local VEGF-A blockade improves the survival rate of corneal transplants. Experimental Eye Research. https://doi.org/10.1016/j.exer.2025.110652

Vancouver

Chen Z, Zhang W, Mestanoglu M, Cursiefen C, Bock F. Promotion of vessel regression by local VEGF-A blockade improves the survival rate of corneal transplants. Experimental Eye Research. 2025. doi:10.1016/j.exer.2025.110652

BibTeX
@article{Chen2025,
  author = {Chen, Zhe and Zhang, Wei and Mestanoglu, Mert and Cursiefen, Claus and Bock, Felix},
  title = {Promotion of vessel regression by local VEGF-A blockade improves the survival rate of corneal transplants},
  journal = {Experimental Eye Research},
  year = {2025},
  doi = {10.1016/j.exer.2025.110652}
}
Kostenlos starten →